New drug hope for lung damage after transplant falls short
NCT ID NCT04908735
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug ruxolitinib to treat early lung damage in children and adults who had a stem cell transplant. Lung problems like bronchiolitis obliterans can be serious and hard to detect early. The trial aimed to see if adding ruxolitinib to standard care could improve lung function. Only 7 people enrolled before the study was stopped early.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS (BO) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ancient herb, modern hope: ashwagandha compound tested to prevent deadly transplant complication
- New study aims to detect lung damage earlier in young transplant patients
- New drug combo aims to keep High-Risk leukemia in remission before transplant
- Rapid test plus targeted antibiotic shows promise for tough infections in blood cancer patients
- New drug hope for lung damage after transplant
- New chemo combo aims to boost leukemia survival after transplant